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Abstract 
Background and Aims: Modelling the population impact and cost-effectiveness of smoking 
cessation aids is limited by lack of knowledge about how the use of aids changes across quit 
attempts. Here we test whether the quit method used in a previous attempt influences (i) future 
decisions to quit and/or (ii) treatment/s used during subsequent attempts. 
 
Design and Setting: Data came from the Smoking Toolkit Study, a United Kingdom national 
household survey. 
 
Participants and Measures: Smokers (n = 5489) who completed a baseline and 6-month follow-up 
questionnaire. Respondents were asked what treatment/s, grouped as: prescription medication/s 
[bupropion, varenicline or nicotine replacement therapy (NRT)], over-the-counter NRT or unaided 
that they had used in their most recent quit attempt (at baseline), and any use of treatment/s for a 
quit attempt in the last 3 months at follow-up. 
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Results: Smokers who had tried to quit at baseline were more likely to report having tried to quit 
again prior to follow-up [all odds ratios ≥ 2.19 relative to no attempt at baseline, P < 0.001]. 
Smokers who tried to quit using pharmacological aids were more likely to try to quit again at follow-
up (all ORs ≥ 2.19 relative to no attempt at baseline, P < 0.001). Smokers tended to re-try aids 
used in baseline attempts in future attempts (all ORs ≥ 1.48 relative to no attempt at baseline, 
P < 0.01). 
 
Conclusions: Smokers who have tried to quit in the past year are more likely to try to quit again 
within 6 months regardless of whether they used a pharmacological aid, and they are more likely to 
re-try aids they had used previously.  
 
Keywords: Smoking cessation, quitting behaviour, cessation medications  
 
Introduction 
 
When modelling the impact of smoking cessation interventions, it is assumed that smokers who do 
not succeed in quitting following the intervention have a similar chance of quitting subsequently as 
the general population of smokers; that is they quit at the ‘background quit rate’ ( 1, 2, 3). However, 
this assumption is unlikely to be correct. For example, it has been shown that smokers who try and 
fail to stop are more likely to try again in subsequent months when followed up ( 4). What is not 
known is how far this applies to specific methods of stopping, such as use of pharmacological aids. 
Neither is it known whether smokers using a given method on one occasion are more or less likely 
to use the same method on subsequent occasions. This paper provides an initial estimate of these 
parameters from a large national sample of smokers in England. 
 
The issue of whether smokers who try to stop using different methods are more or less likely to 
make a subsequent quit attempt has important implications for modelling the longer-term impact of 
those interventions. For example, if failing to stop smoking after using nicotine replacement therapy 
(NRT) bought over the counter (OTC) decreases likelihood of making a subsequent quit attempt, 
this would negatively impact on population quitting rates using this method. This would need to be 
taken into account in any recommendations. On the other hand, if users of OTC NRT were more 
likely to try to stop subsequently if they failed on a given occasion relative to those using other 
methods, this would increase the population impact. Similar, considerations would apply for other 
quitting methods. 
 
The association between the use of different quitting methods on use of the same versus other 
methods is similarly important in terms of longer-term population impact. For example, if smokers 
who use a prescription medicine to stop on one occasion are more likely to use the same method 
again if they fail, this could influence their longer-term chance of quitting successfully. This would 
need to be taken into account in cost-effectiveness modelling. Knowledge of the use of quit 
methods over time is also of interest to clinicians involved in counselling patients to quit. One 
potential detrimental effect of a failed quit attempt is that smokers may attribute failure to the 
medication or treatment used. This raises the concern that a smoker, who fails during an aided quit 
attempt, may be less motivated to quit or use the same, or other treatments, in future quit attempts, 
thus reducing their chances of successfully quitting. If failure negatively impacts on a smoker’s 
likelihood of using a particular treatment again, this would suggest that we need to exercise caution 
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when encouraging the use of any treatment, perhaps only doing so in cases where smokers are 
highly-motivated to make a serious quit attempt, and, in the case of pharmacotherapy in particular, 
only when patients have been educated about the importance of compliance and adherence.  
 
To our knowledge, there is no direct evidence on these issues in the literature and behavioural 
theory suggests several factors that would influence behaviour in different directions. For example, 
it is possible that smokers who fail to stop using a given method that has made it subjectively 
easier (e.g., by reducing craving and withdrawal severity), even though they relapsed, would be 
encouraged to make another attempt and to use the same method again. However, it is also 
possible that failure to quit with a method that they had expected to be effective could discourage 
future quitting attempts and/or lead to switching to another method. In the absence of a steer from 
theory or previous studies the present study has to be considered exploratory. 
 
The present study made use of an on-going surveillance programme in England called the 
Smoking Toolkit Study (STS) ( 5, 6). This consists of a series of monthly household surveys of 
nationally representative samples aged 16+. Questions focus on smoking status, smoking patterns 
and quitting activity. Each month involves a new sample. The study has been in operation since 
November 2006. A number of the monthly surveys have been supplemented by a postal 
questionnaire 6 months later. This provides an opportunity to examine prospective associations 
between quitting activities over two different time points. There are many possible approaches to 
assessing associations between quitting methods and subsequent quit attempts and quitting 
methods, each with strengths and limitations. For this initial study, we chose the simplest approach 
which was to assess the method used in the most recent attempt made in the past 12 months at 
baseline and assess associations between this and 1) whether a subsequent quit attempt was 
recorded at a 6-month follow up (within the last 3 months), and 2) the method used in any such quit 
attempt. We did not assess the more complex modelling of conditional probabilities between 
successive quit attempts where more than one quit attempt was made prior to baseline or between 
the baseline and follow-up would require a larger sample and additional longitudinal data not 
available in the STS. In order to rule out associations arising from sources of common variance 
such as age, gender, social grade and nicotine dependence, we undertook all analyses with and 
without adjustment for these variables. 
 
In England, unaided quitting, OTC NRT, and use of a prescription medication are the most 
commonly used methods ( 7,  8) and therefore STS users of these methods provided sample sizes 
sufficient to obtain parameter estimates with acceptable confidence intervals, given the 
accumulated sample size of the study. Use of behavioural support is common relative to other 
countries but still would not provide an adequate sample size for this study, so was excluded. Thus 
the research question addressed by this study was: after adjusting for important sources of 
common variance, how far is method used to quit in the most recent quit attempt made within the 
past 12 months (in terms of unaided cessation, use of OTC NRT or use of a prescription 
medication) predictive of a) odds of a quit attempt in the next 6 months, and b) quitting method 
among those making at least one attempt. 
 
Methods 
Overview 
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As noted above, data were drawn from the STS. Participants are recruited via random sampling of 
grouped output areas (300 households to each area) stratified by ACORN characteristics ( 9) and 
region. Trained interviewers randomly select households within these areas and conduct face-to-
face computer assisted interviews with one household member (≥16 years old) per residence until 
quotas are reached. For some waves of the STS, subject to funding constraints, 6 months after this 
initial baseline survey, current smokers and recent quitters, who had consented to being re-
contacted, were posted a follow-up questionnaire. Full details of the methodology and sample 
representativeness have been described elsewhere ( 5,  6). 
Sample 
 
The present sample was drawn from current smokers who completed the baseline survey prior to 
April 2012 (when follow ups were suspended) and were successfully followed up. Respondents 
were classified as current smokers at baseline and at follow up if they reported smoking cigarettes 
or tobacco products (e.g., hand rolled, cigar, or pipe) every day or occasionally. Of a baseline 
sample of 25,621 smokers, 5,489 were followed up.  
 
Measures 
Quit attempts in the preceding 12 months were assessed by asking: "How many serious attempts 
to stop smoking have you made in the last 12 months? By serious attempt I mean you decided that 
you would try to make sure you never smoked again. Please include any attempt that you are 
currently making and please include any successful attempt made within the last year". Among 
those reporting at least one attempt, the use of smoking cessation aids was assessed for the most 
recent quit attempt by asking "Which, if any, of the following did you try to help you stop smoking 
during the most recent serious quit attempt? " and respondents could choose between response 
categories; for analysis, we collapsed responses into three groups: i) medication (NRT, bupropion 
or varenicline) provided or prescribed by health-care professional (MED-RX); ii) NRT bought OTC 
(OTC NRT); and (iii) unaided (i.e., had not used any of NRT bought, a prescription stop-smoking 
medication or face-to-face behavioural support). If a smoker reported using OTC NRT and MED-
RX in their most recent quit attempt, they were coded as using MED-RX. [This only occurred in a 
small number (n=28) of cases.] Smokers were also asked how long ago the quit attempt started. 
Note that, as they were all smokers, the quit attempt had not succeeded.  
 
Demographic characteristics (age, gender and social grade) and cigarettes per day (CPD) were 
also assessed at baseline. Social grade was based on the household’s main income earner and 
calculated according to the British National Readership Survey classification system and 
dichotomised into two categories: ABC1 which includes managerial, professional and intermediate 
occupations; and C2DE which includes small employers and own account workers, lower 
supervisory and technical occupations, and semi-routine and routine occupations, never workers, 
and long-term unemployed. 
 
Participants were posted a follow-up questionnaire 6 months after the initial baseline survey. The 
follow-up questionnaire asked similar questions to the baseline survey about quit attempts over the 
past year. To avoid possible overlap between these quit attempts and those recorded at baseline 
we restricted consideration to attempts made in the past 3 months. If more than one quit attempt 
was reported within this time period (n=178), or if more than one method was reported within a 
single attempt, we coded the highest intensity method used (i.e., a respondent was classified as 
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having used MED-RX if they used this and OTC NRT, OTC NRT if they reported any OTC NRT but 
no MED-RX, and as unaided if they reported no use of OTC NRT nor MED-RX). Ethical approval 
was granted by the University College of London Research Ethics Committee. 
 
Analytic plan 
Contingency tables showing the proportions making a quit attempt using different methods at 
follow-up as a function methods of quitting at baseline were prepared. Then simple and multiple 
logistic regressions were undertaken to assess a) the odds of making a quit attempt and b) the 
odds of making a quit attempt using a particular method as a function of method used at baseline. 
In all cases, not having made a quit attempt at baseline was used as the common reference 
category. The multiple regression models controlled for baseline measures of age, gender, social 
grade (ABC1 vs. C2DE), CPD and year of survey. 
 
Results 
Baseline characteristics  
The study sample comprised the 5,489 individuals who returned the follow-up survey; 21.4% of the 
25,621 eligible current smokers surveyed at baseline. Compared with those lost to follow-up, 
respondents in the evaluable sample were older, more likely to be female, smoked a greater 
number of CPD and showed a different pattern of quitting during the year prior to the baseline 
survey (Table 1). The proportion from a routine and manual occupation was similar between the 
two groups.   
 
At baseline, the majority (68.9%) of respondents reported not having made a quit attempt in the 
previous 12 months. Among those who had made a quit attempt (n=1,707), a third (33.3%) 
reported using OTC NRT during their most recent quit attempt and 20.3% reported using 
prescription medications, and approximately half (46.3%) of respondents reported that their most 
recent quit attempt was unassisted. 
 
[Insert Table 1 around here] 
  
Quitting behaviour at 6-month follow-up 
 
Just over a fifth (21.7%; n=1,191) of respondents reported having made a quit attempt in the 3 
months up to the 6-month follow-up survey. Table 2 shows the proportions and odds of making a 
quit attempt at follow-up, based on quitting behaviour at baseline. Compared with smokers who 
reported not having made a quit attempt in the last year at baseline, respondents who reported that 
they had tried to quit at baseline had two to three times greater odds of reporting having attempted 
to quit at follow-up (Table 2). Over a third of respondents who reported having tried to quit 
unassisted during their most recent quit attempt at baseline reported having made a subsequent 
quit attempt at the follow-up survey, compared with just 15.8% of baseline responders who 
reported not having made a quit attempt in the last year at baseline. Similarly, smokers who tried to 
quit using smoking cessation medications at baseline were more likely to report having tried to quit 
again at follow-up (Table 2).  
 
[Insert Table 2 around here] 
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Table 3 shows the association between baseline quitting behaviour and subsequent behaviour at 
follow-up among those participants who reported making quit attempt at the follow-up survey 
(n=1,191). Compared with those who had not attempted to quit in the last year at baseline, 
respondents who indicated that their most recent attempt to quit at baseline had been unaided 
were more likely to also make a subsequent unaided attempt (67.9% versus 76.2%; Table 3). 
Conversely, those who used medications at baseline – either OTC or on prescription – had 
significantly lower odds of attempting to quit unaided at follow-up (Table 3). Similarly, the use of 
OTC NRT or a prescription medication with brief advice at baseline was associated with increased 
odds of using these treatments again at follow-up. 
 
[Insert Table 3 around here] 
 
Discussion 
 
Our results indicate that there are increased odds of making a quit attempt if one has been made in 
the recent past and this is not substantially affected by whether or not the previous attempt 
involved use of pharmacotherapy. They also show that the odds are increased for using  the same 
method as one used before, whether it be no pharmacotherapy, OTC NRT or prescription 
medication. 
 
The results suggest that modelling the impact of use of different pharmacological aids to cessation 
should factor in an adjustment to background quitting rates. In order to know how much to raise 
such rates one would have to have much longer follow-up and would also have to consider the 
chances of success of subsequent quit attempts. This is an important area for future research. 
 
From a clinical and policy perspective, it would seem undesirable that smokers using methods of 
quitting that for them have not proved successful, should show a tendency to use the same method 
again. It would seem reasonable to suggest to smokers who have not succeeded with a lower level 
of support and help that they should try with a higher level of support the next time. If smokers 
have not succeeded with a higher level of support, e.g. a prescription medication, it would seem 
reasonable to examine what more could be done to improve their chances of success next time. 
This might involve using behavioural support, adding additional self-help methods, or using 
whatever method they are using more intensively ( 10). For example, if they had used a single form 
NRT, they could be advised to use a dual form (transdermal patch plus a faster acting form); or 
they could be advised to use higher dose products, use them more often or for longer ( 11). 
 
There is little information on what happens when smokers use the same method of stopping as 
previously but a recent placebo controlled trial found that smokers who had previously used 
varenicline in a quit attempt but resumed smoking, benefitted from using the same medication 
again relative to placebo ( 12). The effect size was similar to what is observed with smokers who 
have not used this medication before, indicating that in this case there is merit in using the same 
method again ( 13).  
 
The study had several limitations. 1) The follow up rate was low and the sample followed up was 
different from that not followed up in relation to a number of factors. However, the differences were 
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small and unlikely to have made a substantial difference to the effect size estimates. In any case, 
these differences (age, gender, CPD, and number of quit attempts made in the previous 12 months 
at baseline) were controlled for in our analyses. 2) Failed quit attempts are often forgotten ( 14, 15) 
and it is possible that this may have influenced the size of the associations observed. If forgetting 
of all types of quit attempt was at the same rate this would not substantially effect the findings but if 
unaided quit attempts are forgotten more quickly than ones using pharmacotherapy ( 14) this could 
bias the results against consistency in use of unaided quitting. 3) The study only looked at quitting 
activity over a period of up to 18 months (12 months prior to the baseline and then leading up to 
the 6-month follow up). Longer-term studies are required. 4) As an initial investigation into the 
issue, this study simplified the task by looking at the most recent quit attempts leading up to the 
baseline surveys. Ideally one would undertake a more comprehensive analysis of the conditional 
probabilities of quitting using different methods. However, this is hampered by the need to adjust 
for background variables and the need to ensure that what are reported as different quit attempts 
really are different, rather than continuations of an existing quit attempt. This requires development 
of an improved methodology for assessing quit attempts. 5) The study did not examine consistency 
in use of specific pharmacotherapies nor other features of the quit attempt (e.g. abrupt versus 
gradual, planned versus unplanned, with or without behavioural support). These are important 
areas for future study. 
 
Despite these limitations, this study provides evidence that whether or not smokers use 
pharmacological aids to a quit attempt does not seem to alter their likelihood of making another 
quit attempt in the following months and that smokers show some consistency in their choice of 
quitting method. It would be worth considering how these finding can be incorporated into cost-
impact models of different smoking cessation interventions. 
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Table 1: Comparison of baseline characteristics of those in the evaluable study sample (n=5,489) 
versus those lost to 6-month follow-up (n=20,132). 
 Study sample 
(n=5,489) 
Lost to follow-up 
(n=20,132) 
Mean age (SD) 47.1 (15.5) 40.9 (16.4)* 
% Female (n) 56.3 (3,089) 50.1 (10,086)* 
% C2DE Social grade (n) 68.2 (3,744) 68.2 (13,725) 
Mean CPD (SD) 14.2 (8.8) 13.1 (8.5)* 
Method used in most recent quit attempt   
No quit attempt (in last 12 months) 68.9 (3,782) 66.3 (13,340)* 
Unaided 14.4 (791) 17.6 (3,551) 
OTC NRT 10.4 (569) 10.8 (2,165) 
Medication on prescription & brief advice 6.3 (347) 5.3 (1,076) 
Notes: OTC NRT = Over-the-counter nicotine replacement therapy. Differences between the two 
groups were assessed with χ2 tests and one-way ANOVAs for categorical and continuous variables 
respectively. * p<.001.  
Page 10 of 11 
 
  
 
Table 2: The association between quitting behaviour at baseline and reporting having made a quit attempt in the last 3 months at  6 months follow-up.  
Quit attempts recorded at baseline 
% reporting having made a quit attempt 
in last 3 months (at follow-up) 
Odds Ratio 95% Confidence Interval 
No attempts to quit in previous 12 months 
(Reference group; n=3,782) 
15.8 (599) - - 
Unaided (n=791) 35.5 (281) 2.98*** 2.50 to 3.55 
OTC NRT (n=569) 37.4 (213) 3.30*** 2.72 to 4.00 
Medication on prescription & brief advice (n=347) 28.2 (98) 2.19*** 1.70 to 2.81 
Notes: OTC NRT = Over-the-counter nicotine replacement therapy. The models are adjusted for all variables listed in Table 1 and the year of the 
survey. *** p<.001. 
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Table 3: The association between quitting behaviour at baseline and treatment use among those who reported attempting to quit in the last 3 months 
at the 6 months follow-up (n=1,191).  
 
Treatment used during  last 3 months prior to 6-months follow-up 
Quit attempts recorded at baseline 
% Unaided  
 (n) 
OR 
(95% CI) 
% OTC NRT 
(n) 
OR 
(95% CI) 
% Med Rx & 
brief advice (n) 
OR 
(95% CI) 
No attempts to quit in previous 12 
months (Reference group; n=599) 
67.9 (407) - 20.0 (120) - 12.0 (72) - 
Unaided (n=281) 76.2 (214) 1.48* 
(1.07 to 2.06) 
16.7 (47) 0.78 
(0.54 to 1.14) 
7.1 (20) 0.61 
(0.36 to 1.02) 
OTC NRT (n=213) 45.5 (97) 0.40*** 
(0.29 to 0.55) 
39.4 (84) 2.57*** 
(1.83 to 3.63) 
15.0 (32) 1.31 
(0.83 to 2.06) 
Medication on prescription & brief 
advice (n=98) 
42.9 (42) 0.38*** 
(0.25 to 0.59) 
30.6 (30) 1.69* 
(1.05 to 2.73) 
26.5 (26) 2.47*** 
(1.47 to 4.14) 
Notes: OTC NRT = Over-the-counter nicotine replacement therapy. Med Rx = medication on prescription. CI = Confidence Interval. All models 
adjusted for all variables listed in Table 1 and the year of the survey. * p<.05, *** p<.001. 
